These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 22534184)

  • 1. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure.
    Kato T; Fukao K; Ohara T; Naya N; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
    J Med Chem; 2023 Aug; 66(16):11428-11446. PubMed ID: 37552807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Robust Read-Across Model for the Prediction of Biological Potency of Novel Peroxisome Proliferator-Activated Receptor Delta Agonists.
    Antoniou M; Papavasileiou KD; Melagraki G; Dondero F; Lynch I; Afantitis A
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel
    Jiang Z; Hu YT; Guo SY; Li YX; Zhao DD; Wei LY; Lin YW; Xu SM; Huang SL; Li Q; Tan JH; Rao Y; Chen SB; Huang ZS
    J Med Chem; 2024 Jul; 67(14):12439-12458. PubMed ID: 38996004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anithiactins A-C, modified 2-phenylthiazoles from a mudflat-derived Streptomyces sp.
    Kim H; Yang I; Patil RS; Kang S; Lee J; Choi H; Kim MS; Nam SJ; Kang H
    J Nat Prod; 2014 Dec; 77(12):2716-9. PubMed ID: 25455147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice.
    Rössger K; Charpin-El-Hamri G; Fussenegger M
    Nat Commun; 2013; 4():2825. PubMed ID: 24281397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
    Nargund RP; Strack AM; Fong TM
    J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
    Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
    Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
    Ham J; Hwang H; Kim E; Kim JA; Cho SJ; Ko J; Lee W; Lee J; Holla H; Banerjee J; Kim S; Yang I; Lee HJ; Shin K; Choi H; Nam SJ; Tak J; Hahn D; Oh T; Won DH; Lee TG; Choi J; Park MS; Seok C; Chin J; Kang H
    Eur J Med Chem; 2012 Jul; 53():190-202. PubMed ID: 22534184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
    Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.